Section
This cohort study reveals a significant pandemic-induced decline in lung cancer screening among US Veterans, with delayed recovery and altered diagnosis patterns, highlighting critical implications for early detection and mortality outcomes
This study analyzes the impact of elective neck dissection (END) on overall survival in patients with cT1-4 N0M0 submandibular gland cancer, revealing that despite a notable rate of occult nodal metastasis, END does not improve survival out
This study evaluates how surgical approach impacts survival and recurrence in low-risk cervical cancer, finding minimally invasive radical hysterectomy safe in low-risk patients but associated with poorer outcomes in high-risk groups.
HB0025, a bispecific antibody targeting PD-L1 and VEGF pathways, combined with chemotherapy, demonstrated encouraging efficacy and manageable safety in advanced non-small cell lung cancer patients, supporting further phase 3 evaluation.
This study demonstrates the promising safety and efficacy of CD20-targeted autologous CAR T-cell therapy in BTKi-refractory Waldenström macroglobulinemia, showing an 80% deep response rate and warranting further investigation in larger tria
This study identifies distinct microbial dysbiosis in laryngeal cancer, highlighting Parvimonas and Campylobacter as potential therapeutic targets based on microbiome profiling of treatment-naive patients compared to controls.
Liver transplantation offers superior long-term survival compared to resection for combined hepatocellular-cholangiocarcinoma, with outcomes comparable to hepatocellular carcinoma when selecting patients without vascular invasion or poor di
This comprehensive review synthesizes emerging evidence supporting a new TNM staging system tailored for poorly differentiated thyroid cancer, demonstrating enhanced prognostic accuracy over existing differentiated thyroid cancer models.
This study uses causal machine learning to reveal that tooth extraction before radiotherapy neither universally reduces nor increases osteoradionecrosis risk, but individualized effects vary substantially, underscoring the need for patient-
Ruzaltatug rezetecan, a HER3-directed antibody-drug conjugate, significantly improves progression-free survival over chemotherapy with manageable safety in EGFR-mutated advanced NSCLC progressing after EGFR TKI therapy.
This population-based study reveals significant differences in pathological response and survival outcomes between stage III melanoma patients with lymph node metastases and those with in-transit metastases treated with neoadjuvant PD-1 inh
This article examines significant improvements in underrepresented racial and ethnic minority representation among oncology trainees post-2020, highlighting progress and ongoing disparities in the oncology workforce.
A phase 1 study demonstrates that low-dose intralesional cemiplimab is safe and achieves high complete response rates in early-stage cutaneous squamous cell carcinoma, supporting further clinical exploration.
This article reviews a study on the impact of timing between postmastectomy radiotherapy and autologous breast reconstruction, highlighting no significant differences in complication rates across various intervals.
This study reveals that preoperative ultrasound frequently overestimates papillary thyroid carcinoma tumor size and has limited accuracy for detecting multifocality and extrathyroidal extension, suggesting caution in surgical decision-makin
VEGFA and EGF polymorphisms differentially affect cholangiocarcinoma susceptibility and postoperative survival, highlighting their potential as biomarkers for clinical stratification.
The NICHE-2 trial demonstrates that neoadjuvant immunotherapy with ipilimumab and nivolumab yields 100% three-year disease-free and five-year overall survival in mismatch repair-deficient colon cancer patients, marking a potential new stand
Spatial proteomics reveals how EGFR and KRAS mutations distinctly remodel the immune microenvironment in non-small cell lung cancer, identifying immune niches and prognostic markers that may guide immunotherapy strategies.
A pivotal phase 3 trial demonstrates improved event-free and overall survival with perioperative durvalumab combined with neoadjuvant enfortumab vedotin, with or without tremelimumab, versus surgery alone in muscle-invasive bladder cancer p
FGFR alterations, especially in FGFR3 and FGFR2, are pivotal biomarkers in urothelial carcinoma, advancing personalized diagnosis, treatment, and monitoring across disease stages. Emerging molecular diagnostics and targeted therapies promis
